Youngster I et al., 2010-09-01: Evidence-based review of medication use in G6PD deficiency, which names methylthioninium chloride (methylene blue) among only seven currently used medications with solid evidence to prohibit.
Although drug-induced haemolysis is considered the most common adverse clinical consequence of G6PD deficiency, significant confusion exists regarding which drugs can cause haemolytic anaemia in patients with G6PD deficiency.
Youngster I et al., 2010-09-01: Evidence-based review of medication use in G6PD deficiency, which names methylthioninium chloride (methylene blue) among only seven currently used medications with solid evidence to prohibit. Study type: review.
